---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000113"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-09-08T12:01:57+00:00"
generated_at: "2026-09-08T12:05:07.874912+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Spyre SPY003 Phase 2 UC: 10-point RHI reduction (p<0.0001), 20% remission, 30% endoscopic improvement

## Summary
- SPY003 met primary endpoint: 10.0-point reduction in RHI from baseline at Week 12 (p<0.0001) in 44 patients with moderate-to-severe UC.
- Secondary endpoints: 20% clinical remission by modified Mayo Score, 30% endoscopic improvement, -3.5 change in mMS.
- Safety: 19 TEAEs (43%), 3 SAEs deemed not drug-related, no drug-related SAEs or deaths; consistent with IL-23 class.
- Completes proof-of-concept for all three IBD components (SPY001, SPY002, SPY003); Part B combination trial enrolling, topline data expected 2027.
- Additional readouts: SKYWAY (SPY072) 4Q 2026; SKYLIGHT (HS) late 2027/early 2028.

## SEC filing metadata
- accession: 0001636282-26-000113
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-09-08T12:01:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/0001636282-26-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000113
- JSON: https://secwatch.observer/filing/0001636282-26-000113.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.